How have RGRX shares performed in 2024?

RegeneRx Biopharmaceuticals' stock was trading at $0.0012 at the start of the year. Since then, RGRX stock has increased by 16.7% and is now trading at $0.0014. View the best growth stocks for 2024 here .

When did RegeneRx Biopharmaceuticals' stock split?

RegeneRx Biopharmaceuticals's stock reverse split before market open on Monday, August 14th 2023. The 1-100 reverse split was announced on Monday, August 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC) , Fulcrum Therapeutics (FULC) , OPKO Health (OPK) , VBI Vaccines (VBIV) , Vaxart (VXRT) , AVEO Pharmaceuticals (AVEO) , Palatin Technologies (PTN) , Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA) .

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:RGRX

RegeneRx Biopharmaceuticals (RGRX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free RGRX Stock Alerts

$0.0014

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.0014
▼
$0.0014
50-Day Range: $0.00
▼
$0.05
52-Week Range: $0.00
▼
$8.80

Volume: 241 shs
Average Volume: 193 shs
Market Capitalization: $2,114.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials SEC Filings Short Interest

Get RegeneRx Biopharmaceuticals alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About RegeneRx Biopharmaceuticals Stock (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

RGRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RGRX Stock News Headlines

November 5, 2023 | morningstar.com

Regenerx Biopharmaceuticals Inc RGRXD

October 31, 2023 | investing.com

Regenerx Biopharm In (RGRXD)

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 21, 2023 | businesswire.com

LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China

August 26, 2023 | seekingalpha.com

RGRX RegeneRx Biopharmaceuticals, Inc.

August 15, 2023 | finance.yahoo.com

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations

August 8, 2023 | finance.yahoo.com

RegeneRx Receives Stockholder Approval for Reverse Stock Split

August 1, 2023 | finance.yahoo.com

RegeneRx To Extend Consent Solicitation Vote

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

July 7, 2023 | thestreet.com

Bristol-Myers to Split Off Mead Johnson

May 19, 2023 | thestreet.com

PlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage Initiation

April 13, 2023 | finance.yahoo.com

First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

April 7, 2023 | marketwatch.com

Biopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030

April 7, 2023 | marketwatch.com

Biopharmaceutical Third Party Logistics (3PL) Market | 2023-2029

March 1, 2023 | marketwatch.com

2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029

February 25, 2023 | marketwatch.com

Biopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028

February 24, 2023 | marketwatch.com

Biopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027

February 12, 2023 | finance.yahoo.com

Biopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

January 31, 2023 | finance.yahoo.com

Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

January 27, 2023 | markets.businessinsider.com

$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

January 18, 2023 | marketwatch.com

Biopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]

January 17, 2023 | marketwatch.com

Biopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the Report

January 3, 2023 | finance.yahoo.com

Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

November 18, 2022 | finance.yahoo.com

Biopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic Partnerships

October 24, 2022 | finance.yahoo.com

RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

September 30, 2022 | investing.com

Clover Biopharmaceuticals Ltd (2197)

September 27, 2022 | finance.yahoo.com

RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

See More Headlines

Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:RGRX
Previous Symbol: OTC:RGRX
CUSIP: N/A
CIK: 707511
Web: www.regenerx.com
Phone: (301) 208-9191
Fax: 301-280-1996
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 0.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.40) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 1,510,000
Free Float: 1,319,000
Market Cap: $2,114.00
Optionable: Not Optionable
Beta: 2.57

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Allan L. Goldstein Ph.D. (Age 86)
Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board
Comp: $86.54k
Mr. J. J. Finkelstein (Age 72)
President, CEO & Director
Comp: $75.26k

Key Competitors

View All Competitors

RGRX Stock Analysis - Frequently Asked Questions

How have RGRX shares performed in 2024?: RegeneRx Biopharmaceuticals' stock was trading at $0.0012 at the start of the year. Since then, RGRX stock has increased by 16.7% and is now trading at $0.0014.
View the best growth stocks for 2024 here.
When did RegeneRx Biopharmaceuticals' stock split?: RegeneRx Biopharmaceuticals's stock reverse split before market open on Monday, August 14th 2023. The 1-100 reverse split was announced on Monday, August 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
What other stocks do shareholders of RegeneRx Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA).
How do I buy shares of RegeneRx Biopharmaceuticals?: Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RGRX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial